Switch to Stribild versus continuation of NVP or RPV with FTC and TDF in virologically suppressed HIV adults: a STRATEGY-NNRTI subgroup analysis

INTRODUCTION: Switch to Stribild (STB) was non-inferior to continuation of a non-nucleoside reverse transcriptase inhibitor (NNRTI) with emtricitabine and tenofovir DF (FTC/TDF) at week 48 in virologically suppressed HIV adults [1]. We report the Week 48 efficacy and safety of STB versus nevirapine...

Descripción completa

Detalles Bibliográficos
Autores principales: Stellbrink, Hans-Juergen, Antinori, Andrea, Pozniak, Anton, Flamm, Jason, Bredeek, Fritz, Patel, Kiran, Garner, Will, Piontkowsky, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International AIDS Society 2014
Materias:
Poster Sessions – Abstract P261
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4225425/
https://www.ncbi.nlm.nih.gov/pubmed/25397537
http://dx.doi.org/10.7448/IAS.17.4.19793

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4225425/
https://www.ncbi.nlm.nih.gov/pubmed/25397537
http://dx.doi.org/10.7448/IAS.17.4.19793

Ejemplares similares